Gastrointestinal cancers (including gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer)
Conditions
Interventions
None listed
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be included: 1.Diagnosed with gastrointestinal cancer (esophageal, gastric, colorectal, hepatic, biliary tract, or pancreatic cancer) 2.Scheduled to initiate cancer pharmacotherapy 3.Provided written informed consent for participation in this study (informed consent will be obtained as described in Section 7.1) 4.Aged 18 years or older
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded: 1.Patients from whom written informed consent could not be obtained (for the retrospective chart review, patients who have expressed refusal for the use of their information in this study, either by themselves or via a proxy) 2.Patients deemed inappropriate for inclusion in the study by the treating physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the presence or absence of deterioration in quality of life from baseline to 3 months after initiation of cancer pharmacotherapy. | — |
Countries
Japan
Contacts
Public ContactHikaru Sato
Hamamatsu University School of Medicine Hospital Department of Pharmacy
Outcome results
None listed